Adipo Therapeutics, LLC

IN · Founded 2016 · CIK 0001823434 · Biotech · Private

A targeted drug delivery system for Notch signaling inhibitors to selectively deliver dibenzazepine to adipose tissue for browning of white adipocytes

Grants
$198K
1 award
Sector median: 1
Raised
$6.0M
2 Form D · Dec 2024
22 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Polymeric nanoparticles for inductive browning of white adipose tissue$198,323
Private capital raisedForm D · SEC$1,250,000
Private capital raisedForm D · SEC$4,717,337
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3362ACTINOBAC BIOMED, INC.—$3.4M
3363Vernal Biosciences, Inc.—$22M
3364AVICANNA INC.—$10M
3365Adipo Therapeutics, LLC—$6.0M
3366Adcendo——
3367SYNERGYS BIOTHERAPEUTICS, INC.——
3368COLLABORATIONS PHARMACEUTICALS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Michael ClaymanDirector
  • Meng DengDirector · Executive Officer
  • Keith JohnsExecutive Officer
  • Karen WursterDirector · Executive Officer

Patents

USPTO · 0 granted of 2
  • Processes For Preparing Nanoparticlesapplication
  • Processes For Preparing Nanoparticlesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.